TRINITY BIOTECH PLC-SPON ADR (TRIB) Forecast, Price Target & Analyst Ratings
NASDAQ:TRIB • US8964385046
0.7288 USD
0 (-0.41%)
At close: Mar 6, 2026
0.7101 USD
-0.02 (-2.57%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TRINITY BIOTECH PLC-SPON ADR (TRIB).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateApr 3, 2026
PeriodQ3 / 2025
EPS Estimate-$0.21
Revenue Estimate17.34M
ChartMill Buy Consensus
85.71%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.73 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
TRIB was analyzed by 7 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about TRIB.
In the previous month the buy percentage consensus was at a similar level.
TRIB was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 3, 2026
PeriodQ3 / 2025
EPS Estimate-$0.21
Revenue Estimate17.34M
Revenue Q2Q14.44%
EPS Q2Q53.43%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
TRIB is expected to report earnings on 4/3/2026. The consensus EPS estimate for the next earnings is -0.21 USD and the consensus revenue estimate is 17.34M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 62.521M -22.96% | 56.832M -9.10% | 61.555M 8.31% | 69.87M 13.51% | 79.05M 13.14% | |
| EBITDA YoY % growth | -11.184M -221.54% | -14.163M -26.64% | -14.193M -0.21% | N/A | N/A | |
| EBIT YoY % growth | -13.517M -309.31% | -15.94M -17.93% | -16.058M -0.74% | -6.114M 61.93% | 1.295M 121.18% | |
| Operating Margin | -21.62% | -28.05% | -26.09% | -8.75% | 1.64% | |
| EPS YoY % growth | -6.25 -366.41% | N/A 90.37% | -2.68 -346.00% | -0.92 65.80% | -0.50 45.56% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.21 53.43% | -0.17 84.79% | -0.19 32.14% | -0.11 54.17% | -0.14 33.33% | -0.05 70.59% |
| Revenue Q2Q % growth | 17.34M 14.44% | 18.36M 15.78% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -1.316M 48.56% | -510K 94.12% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
TRINITY BIOTECH PLC-SPON ADR / TRIB Forecast FAQ
What is the next earnings date for TRIB stock?
TRINITY BIOTECH PLC-SPON ADR (TRIB) will report earnings on 2026-04-03, before the market open.
Can you provide the consensus estimates for TRINITY BIOTECH PLC-SPON ADR next earnings?
The consensus EPS estimate for the next earnings of TRINITY BIOTECH PLC-SPON ADR (TRIB) is -0.21 USD and the consensus revenue estimate is 17.34M USD.
What is the consensus rating for TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?
The consensus rating for TRINITY BIOTECH PLC-SPON ADR (TRIB) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.